Related terms
- Retina
- The light-sensitive layer at the back of the eye. Light that is too intense can damage it, which is why eye safety is assessed for any light device used near the face.
- FDA 510(k) clearance
- A US Food and Drug Administration decision that a device is substantially equivalent to one already on the market for a stated use. It is not a finding that the device works for any particular condition.
Research that mentions age-related macular degeneration
51 studies in our archive have this term in the title. The newest are below.
Cost-Effectiveness of Photobiomodulation for Intermediate Dry Age-Related Macular Degeneration: A Model-Based Analysis Using the LIGHTSITE III 24-Month Trial
PBM is cost-effective at conventional US willingness-to-pay thresholds, driven primarily by a 71.7% relative reduction in incident GA at 24 months.
Non-advanced age-related macular degeneration: Current concepts and future perspectives
Future research priorities include validation of quantitative imaging and functional endpoints, integration of artificial intelligence-based predictive models, and development of targeted therapies to delay progression.
Photobiomodulation in Age-Related Macular Degeneration: A Mitochondrial Bioenergetic Framework and Translational Perspective
We propose a conceptual framework in which PBM responses are governed by the interaction between a dose-dependent bioenergetic window and the mitochondrial functional reserve of retinal cells.
12-month outcomes of photobiomodulation in dry age-related macular degeneration: a prospective multicentre randomised double-masked controlled clinical trial
PBM significantly reduced drusen burden and improved visual function in early and intermediate dAMD over 12 months, with an excellent safety profile.
Functional and Structural Outcomes of Photobiomodulation Therapy in Dry Age-Related Macular Degeneration: A Single-Center Experience
PBM therapy demonstrated limited short-term anatomical change but variable functional outcomes in dry AMD. Baseline BCVA emerged as the primary determinant of visual response, suggesting that treatment benefit may be influenced predominantly by pre-treatment functional reserve.
LONG-TERM EFFICACY AND SAFETY OF PHOTOBIOMODULATION IN DRY AGE-RELATED MACULAR DEGENERATION (LIGHTSITE III: 24-MONTH ANALYSIS)
Multiwavelength PBM represents an interventional therapy that restores visual function and has potential disease-modifying effects in intermediate dry AMD.
Read this with care
- This entry is general information, not medical advice. See the disclaimer.
- Definitions are written for readers new to the field and may be simplified. Check the full paper when it matters.
- Found a mistake? Tell us.